**NextCure’s IND Application for LNCB74 Accepted by FDA for Phase 1 Clinical Trial Evaluation**BELTSVILLE, Md. – NextCure, Inc. (Nasdaq: NXTC) revealed today that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (I

**

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read NextCure’s 8K filing here.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.